Molecular Formula | C21H19BrClN5O4S2 |
Molar Mass | 584.89 |
Appearance | Light beige solid |
Storage Condition | +2C to +8C |
In vitro study | ZCL278 inhibits the activity of Cdc42 GTPase by competing with GTP, and shows a time-dependent relationship in the inhibition of Rac/Cdc42 phosphorylation. ZCL278 (50 μm) inhibits Cdc42-mediated microprojection formation, disrupting the GM130-linked Golgi structure in serum-starved Swiss 3T3 fibroblasts. ZCL278 was also able to inhibit Cdc42-mediated neuronal branching, growth cone kinetics and actin-mediated motor migration capacity in metastatic prostate cancer cell line PC-3 without cytotoxicity. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
10 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
biological activity | ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM. |
in vitro study | ZCL278 inhibits the activity of Cdc42 GTPase by competing with GTP, showing a time-sensitive relationship in the inhibition of Rac/Cdc42 phosphorylation. ZCL278 (50 μM) inhibits Cdc42-mediated microprocess formation, disrupting the GM130-linked Golgi structure in serum-starved Swiss 3T3 fibroblasts. ZCL278 can also inhibit Cdc42-mediated neuronal branching, growth cone dynamics and actin-mediated motor migration in metastatic prostate cancer cell line PC-3, and has no cytotoxicity. |